Concise Review: Embryonic Stem Cells Versus Induced Pluripotent Stem Cells: The Game Is On

Authors

  • Mira C. Puri,

    1. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    2. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
    • Author contributions: M.C.P. and A.N.: researched and wrote this review.

    • Disclosure of potential conflicts of interest is found at the end of this article.

    • First published online in STEM CELLSEXPRESS November 18, 2011.

  • Andras Nagy

    Corresponding author
    1. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    2. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    3. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Box 40, Toronto, Ontario M5T-3L9, Canada
    Search for more papers by this author

Abstract

Extraordinary advances in pluripotent stem cell research have initiated an era of hope for regenerative strategies to treat human disease. Besides embryonic stem cells, the discovery of induced pluripotent stem cells widened the possibility of patient-specific cell therapy, drug discovery, and disease modeling. Although similar, it has become clear that these two pluripotent cell types display significant differences. In this review, we explore current knowledge of the molecular and functional similarities and differences between these two cell types to emphasize the necessity for thorough characterization of their properties as well as their differentiation capabilities in the pluripotent state. Such comparative studies will be crucial for determining the more suitable cell type for future stem cell-based therapies for human degenerative diseases. STEM CELLS 2012;30:10–14

Ancillary